Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
about
Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic AneurysmDesign of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization.Cathepsin S: therapeutic, diagnostic, and prognostic potential.Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cellsCysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease.
P2860
Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@ast
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@en
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@nl
type
label
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@ast
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@en
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@ast
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@en
Pharmacokinetics and pharmacod ...... Y3000328, in healthy subjects.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... LY3000328, in healthy subjects
@en
P2093
David J DeBrota
Elizabeth Smith LaBell
Lai Hock Tan
Mark A Deeg
Melanie Chan
P2860
P304
P356
10.1111/BCP.12470
P407
P577
2014-12-01T00:00:00Z